Abstract | OBJECTIVE: METHODS: We searched the pertinent literature from January 1990 to August 2017. Two reviewers evaluated and screened the literature independently for eligibility and extracted data. We evaluated the quality of body of evidence and made a recommendation according to the Grading of Recommendations Development and Evaluation methodology. RESULTS: The search yielded 40 studies, 9 of which were included after the first and second screenings. There were three prospective case series but no randomized controlled trials among the nine studies. There was no case-control report (vs. no treatment). According to Response Evaluation Criteria in Solid Tumors criteria, the mean response rate (complete remission or partial response) was 36% (11-57%). Including stable disease, namely, clinical benefit was consistently as high as 85% (69-100%). Mean adverse event rate of G3 or G4 according to CTCAE was 31%. One study reported improvement of pain (87.5%) because of this chemotherapy. CONCLUSION:
|
Authors | Koki Shimizu, Shunsuke Hamada, Tomohisa Sakai, Hiroshi Koike, Masahiro Yoshida, Yoshihiro Nishida |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 50
Issue 4
Pg. 419-424
(Apr 07 2020)
ISSN: 1465-3621 [Electronic] England |
PMID | 31845730
(Publication Type: Journal Article, Systematic Review)
|
Copyright | © The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected]. |
Chemical References |
|
Topics |
- Abdomen
(pathology)
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Case-Control Studies
- Dose-Response Relationship, Drug
- Female
- Fibromatosis, Aggressive
(drug therapy)
- Humans
- Male
- Methotrexate
(administration & dosage, therapeutic use)
- Prospective Studies
- Remission Induction
- Treatment Outcome
- Vinblastine
(administration & dosage, therapeutic use)
|